Company intelligence / Profile preview

Memgen

Houston, Texas, United Statesmemgenbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MEM-288 demonstrated tumor shrinkage and disease control in 50% of advanced NSCLC patients with only mild and transient treatment-related side effects. The therapy showed signs of anti-tumor immune response generation, with the ability to shrink tumors and increase immune response even in stage 4 patients who had multiple prior treatments[1][5].

Therapeutic areas: Oncology
Modalities: Viral immunotherapiesCell-based immunotherapies (TILs)Infectious disease vaccine adjuvants
Industry: Biotech

Drug pipeline

2 assets

ISF35

1 more asset in the full pipeline.

Request access →

Partnerships

Moffitt Cancer Center

Beyond the preview

Go deeper on Memgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Memgen.

Explore the full profile